Drug intelligence / Profile preview

Rabifast

Development stage: Unknown
Lead developer: Zuventus Healthcare
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Rabifast is a brand of rabeprazole sodium, a substituted benzimidazole and proton pump inhibitor (PPI) developed and marketed by Zuventus Healthcare. It functions by covalently binding to and inhibiting the H+/K+-ATPase enzyme (the gastric proton pump) on the secretory surface of gastric parietal cells, thereby blocking the final step of gastric acid secretion. Rabifast is indicated for the treatment of acid-related disorders, including duodenal ulcers, benign gastric ulcers, and gastro-esophageal reflux disease (GERD). It is available in various formulations, including enteric-coated tablets and combination products with prokinetic agents like domperidone or levosulpiride.

Brand names: Rabifast
Other names: rabeprazole sodium

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Rabifast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rabifast.

Explore the full profile